Sample Diabetes Care Flow Sheet

Name	:						of diabetes		Date o	of birth:			Age at diagnosis:	
Comorbidities, Risk Factors Date:					е:				Self-management (discuss and sh				share decisions)	
☐ Hypertension (target <130/80)									Priorities and Goals:					
☐ Dysli	oidemia													
□ CVD □ Smoking				(date stopped)			Possible Barriers to Self –management							
□ HF □ Alcohol/			(data stopped)			Colf management Education								
			other	substances	:	(assess/discussed)			Self-management Education Weight management:					
□ CKD			□ Mei	ntal Health	Diagno	sis		Baseline weight: Wt. Ht:						
			ot disease						Baseline BMI: (Healthy BMI 18.5–24.9)					
□ PAD □ Retinopathy								□ Physical activity (150 min/week- aerobic/ resistance 2-3 times a week)						
□ ED □ Family Histor			mily History	,				☐ Glucose meter/lab comparison						
□PCOS							☐ Patient care plan (including pregnancy planning) ☐ Driving Guidelines							
							Visits	to 6 months)						
Date	BP	Weig as requi		A1C (Target < 7% or	No	otes (cond	cerns, goals, status)	clinical	Нурос	glycemia		Allergies, si	ion Baseline and Changes: de effects, contraindications. ARB, antihyperglycemics as indicated	
				,										
	0110	_		- ,						- 10			15.440	
Revie	w SMB	G reco	ords. I	l arget: pi	remea								if A1C not at target)	
N .		N/P 1) FD : 61	0 1' '	ı			tes comp	lication	s annua	ally or as in	aicated		
	pathy: 0 R >2 mg		¢ >ארכ	0 ml/min		□ Neuro		and concett	n (10 ~ ~	nofilome	t or 128 Hz tunin	a fork)	☐ Retinopathy	
Date	ACR	<i>y</i> /1111101		eGFR			for pain, ED, G		on (10-g mc	moniamen	l 01 120 HZ lufilfi	ig iork)	Annual eye exam: Date:	
				-		Date:	Finding	, ,					Date:	
						Date:	Finding	is: 6896)Ar ₂		£889933		Ophthalmologist/Optometrist:	
						Date:	Finding	ıs:						
	cular pr	otectio	ı (see b	ack for		☐ Lipids	Targets: If in	idicated to tre	at:				□ Vaccinations	
details		0 . 0		. 45			D		nati I DI	40	- 1/1			
☐ Statins if ≥ 40 yrs Or > 30 yrs and >15 yrs dura				ation	Date	Medication	rimary tar	HDL-C	TG	(Non-HDL-C)	(Apo B)	Annual influenza Date:		
 ☐ Statins if ≥ 40 yrs Or > or end organ damage ☐ ACE /ARB if macro or 			icro vsc	disease or >	55	Dale	ivieuication	LDL-C	TIDE-C	10	(INOII-UDL-C)	(Αρυ Β)	Date:	
☐ ACE /ARB if macro or micro yrs with 1 CVD risk factor			. 5. 5 +00.	3.000000										
	☐ SGLT2i or GLP1-RA: Consider if ASCVD, HF, CKD				CKD								Pneumococcus	
	sessme												Date:	
□ ECG (see back)														
Stress ECG:Other:														

See reverse side for care objectives and targets

Care	Objective	Target
Self-monitoring	Ensure proper use of glucose meter, flash meter, or CGM. Interpret results	Premeal (mmol/L) = 4.0-7.0 for most people
of Blood Glucose	and modify treatment as needed. Develop blood glucose monitoring schedule using goals and shared decisions. Review records.	2hr Postmeal (mmol/L) 5.0 -10.0 for most people with DM 5.0 -8.0 if not achieving A1C target
Blood Glucose Control	Measure A1C every three months for most adults Consider testing at least every 6 months in adults during periods of treatment and lifestyle stability when glycemic targets have been consistently achieved. Understand when A1C is not accurate. (eg CKD). Check accuracy of meter with laboratory annually	A1C ≤ 7.0 % for most people with DM Individualized based on patient and agent Characteristics. Simultaneous fasting glucose/meter lab comparison within 20%.
Regular Review Adjust Treatment	Regular review of clinical status: Advance / adjust AHA if not at target and identify those with ASCVD, HF, CKD who may require adjustments even is at target	Add or substitute AHA with cardiorenal benefit (SGLT2i / GLP1RA). Even if A1C is at target
Nutrition	Encourage individualized nutritional therapy (by a registered dietitian) as an integral part of treatment and self-management (can reduce A!C by 1-2%). If overweight or obesity is present, strategies that include energy restriction to achieve a modest weight loss of 5% to 10% of initial body weight are a primary consideration.	To attain and maintain a healthy or lower body weight for the long term, to prevent further weight gain or to prevent weight regain while meeting nutritional needs.
Physical Activity	Discuss and encourage aerobic and resistance exercise. Evaluate those with possible CVD or microvascular complications undertaking exercise substantially more vigorous than brisk walking	Aerobic: ≥ 150 minutes /week Resistance: 3 sessions/week
Body Mass Index	Calculate BMI (mass in kilograms/height in metres2)	Healthy body weight target: BMI: 18.5 – 24.9
Smoking	Encourage smoking cessation at each visit; provide support as needed	Smoking cessation
CVD Risk Identification and Protection	Review for presence of CVD disease Conduct CVD risk assessment periodically: CV history, lifestyle, duration of DM, sexual function, abdominal obesity, lipid profile, BP, reduced pulses, bruits, glycemic control, retinopathy, eGFR, ACR. Resting ECG every 3-5 years if any of: age > 40 years, duration of DM>15yrs.+>30yrs,end organ damage(microvasc. or CVS)),>1 CV risk factor.	Vascular Protection: First priority in prevention of diabetes complications is reduction of cardiovascular risk by vascular protection through a comprehensive multifaceted approach All people with DM: optimize: BP, glycemic control and healthy behaviours Statin if: age ≥ 40y or macrovascular disease OR if <40y + microvascular disease or long duration of DM (DM>15yr and age >30y) ACE-I or ARB if CVD or microvsc. disease or >55 yrs with 1 CVD risk factors Use of AHA (SGLT2i or GLP1-RA) EVEN if at A1C target for those with ASCVD, CKD,HF,>60yrs.+CVrisk factors
Hypertension	Measure BP at diagnosis and at every diabetes clinic visit	<130/80
Dyslipidemia	Fasting lipid levels (TC, HDL, TG and calculated LDL) at diagnosis, then yearly if treatment not initiated. More frequent testing if treatment initiated.	Lipid targets for those who need therapy: Primary target: LDL < 2.0 mmol/L or >50% reduction. Alternate Primary target: apo B < 0.8 g/L or non-HDL-C < 2.6 mmol/L
Retinopathy	Type 1 diabetes Screen 5 years after diagnosis, then rescreen annually Type 2 diabetes Screen at diagnosis and 1-2 years after initial screening if no retinopathy is present. The interval for follow-up assessment should be tailored to the severity of the retinopathy. Screening conducted by an experienced eye care professional	Early detection and treatment
Chronic Kidney Disease	Identification of CKD requires screening for proteinuria using random urine ACR (2 out of 3 samples over 3 mths.) and assessment of renal function using a serum creatinine converted to eGFR. Type 1 diabetes Screen at 5 years duration and then annually if no CKD Type 2 diabetes— Screen at diagnosis and then yearly if no CKD If CKD present, ACR and eGFR should be done at least every 6 months	ACR (mg/mmol) < 2.0 eGFR > 60 mL/min
Neuropathy/ Foot examination	Type 1 diabetes – Screen 5 years duration and annually Type 2 diabetes – Screen at diagnosis, then annually Screen for neuropathy with 10-g monofilament or 128 Hz tuning fork at dorsum of great toe. In foot exam look for: structural abnormalities, neuropathy, vascular disease, ulceration, infection	Early detection and treatment. If neuropathy present: require foot care education, specialized footwear, smoking cessation. If ulcer present: manage by multidisciplinary team with expertise
Immunizations	Recommend annual influence vaccination. Recommend pneumo-vax 23	
Populations with Mental Health Concerns	Liaise with mental health-care professionals where necessary to ensure appropriate care plans are developed that include psychosocial interventions and glycemic control	Mental health treatments may improve diabetes outcomes

Care Objectives: People with diabetes will have better outcomes if primary care providers 1) identify people with diabetes in their practices 2) assist them by incorporating the suggested care objectives; 3) schedule diabetes-focused visits; 4) use diabetes flow sheets and systematic recall for visits